文献速递主动脉疾病

胸主动脉腔内修复术中保留左锁骨下动脉的定制与即用型覆膜支架结局:系统综述与荟萃分析

Outcomes of Custom Made and Off the Shelf Endografts for Preservation of the Left Subclavian Artery during Thoracic Endovascular Aortic Repair: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2026-03-27

汇总技术成功率98.75%,30天死亡率0.87%,30天卒中率1.32%,脊髓缺血率0.06%,12个月死亡率2.5%。证据确定性低,异质性大,结果外推受限。

要点

  • 单分支/单开窗覆膜支架保留LSA技术成功率高(98.75%),围术期卒中与脊髓缺血率低。
  • 即用型器械占23.7%,定制型占76.3%,12个月死亡率2.5%。
  • 证据确定性低,异质性大,部分器械仅亚洲可用,需在高容量中心选择患者。

核心结论

  • 尽管证据确定性低,定制与即用型单分支或单开窗覆膜支架在TEVAR中保留LSA显示出有前景的可行性、安全性和耐久性。

研究设计与样本

  • 纳入标准为使用单分支或单开窗覆膜支架(即用型或定制型)保留LSA治疗主动脉病变的研究。
  • 采用ROBINS-I评估偏倚风险,GRADE框架评估证据确定性,进行比例荟萃分析报告95%CI。

主要发现

  • 最常见适应证为B型主动脉夹层,其次为胸主动脉瘤。
  • 即用型器械使用率23.7%,定制型76.3%。
  • 汇总技术成功率98.75%(95%CI 97.89-99.49%),30天死亡率0.87%(95%CI 0.22-1.81%)。
  • 30天卒中率1.32%(95%CI 0.51-2.38%),脊髓缺血率0.06%(95%CI 0-0.59%)。
  • 12个月死亡率2.5%(95%CI 1.27-4.02%)。

关键数值与推荐

  • 按地理区域亚组分析显示,欧洲和北美研究卒中及30天心血管事件发生率更高,亚洲研究12个月靶血管闭塞率更高。

临床怎么用

  • 在高容量中心,对选定患者使用定制或即用型单分支/单开窗覆膜支架保留LSA可行且安全。
  • 需注意证据确定性低及器械可及性差异,临床决策应结合患者个体情况和中心经验。

局限性

  • 证据总体确定性低(GRADE)。
  • 存在显著的临床和方法学异质性。
  • 部分器械仅在亚洲可用,限制结果外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This systematic review aimed to evaluate the safety, feasibility, and effectiveness of dedicated endovascular techniques for left subclavian artery (LSA) preservation during thoracic endovascular aortic repair (TEVAR) (PROSPERO CRD42024568126). DATA SOURCES: MEDLINE, Scopus, Embase, and Cochrane Library databases. REVIEW METHODS: A systematic literature search followed the PRISMA guidelines. Eligible studies reported on patients with aortic pathologies treated with a single branched or single fenestrated endograft, off the shelf or custom made, intended for preservation of the LSA. Risk of bias was assessed using the Cochrane ROBINS-I tool, and the certainty of evidence using the GRADE framework. A proportion meta-analysis was performed reporting pooled rates with 95% confidence intervals (CIs). RESULTS: Twenty-one studies (1 123 patients) published between 2015 and 2024 were included. The most common indication for treatment was type B aortic dissection, followed by thoracic aneurysm. Off the shelf devices were used in 23.7% and custom made devices in 76.3%. The pooled technical success rate was 98.75% (95% CI 97.89 - 99.49%) and 30 day mortality rate was 0.87% (95% CI 0.22 - 1.81%). The pooled 30 day stroke rate was 1.32% (95% CI 0.51 - 2.38%) and spinal cord ischaemia rate 0.06% (95% CI 0 - 0.59%). At 12 months, the pooled mortality rate was 2.5% (95% CI 1.27 - 4.02%). A subgroup analysis stratified by geographical region (Asian vs. European and North American studies) showed a higher incidence of stroke and 30 day cardiovascular events in European and North American studies, and higher 12 month target vessel occlusion rates in Asian studies. However, according to the GRADE classification, the overall certainty of the evidence was low. Considerable clinical and methodological heterogeneity and the use of devices not available outside Asia further limit the generalisability of the results. CONCLUSION: Despite the low evidence of the available data, the use of custom made and off the shelf single branched or fenestrated endografts for LSA preservation during TEVAR shows promising feasibility, safety, and durability in selected patients managed at high volume centres.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Amvrazi AV, Antonopoulos CN, Spath P, et al. Outcomes of Custom Made and Off the Shelf Endografts for Preservation of the Left Subclavian Artery during Thoracic Endovascular Aortic Repair: A Systematic Review and Meta-analysis. Eur J Vasc Endovasc Surg. 2026. PMID: 41905582. doi:10.1016/j.ejvs.2026.03.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。